VBI Vaccines Inc.
NASDAQ: VBIV0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jeffery R. Baxter FCMA
- Employees
- 131
- Headquarters
- Cambridge, United States
- IPO year
- 2010
- Market cap
- $1.9M
- Website
- https://www.vbivaccines.com
Loading VBIV…
Loading profile data…Frequently asked questions about VBIV
What does VBI Vaccines Inc. (VBIV) do?
VBI Vaccines Inc. is a biopharmaceutical firm dedicated to the development and commercialization of vaccines, targeting both infectious diseases and immuno-oncology. Among its commercial offerings is Sci-B-Vac, a prophylactic vaccine designed to prevent hepatitis B (HBV). The company is also actively developing VBI-2601 (also identified as BRII-...
Where does VBIV trade?
VBI Vaccines Inc. (VBIV) trades on the NASDAQ Capital Market.
What sector is VBIV in?
VBI Vaccines Inc. (VBIV) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of VBI Vaccines Inc.?
Jeffery R. Baxter FCMA is the chief executive officer of VBI Vaccines Inc. (VBIV).
Where is VBI Vaccines Inc. headquartered?
VBI Vaccines Inc. is headquartered in United States.
Does VBIV pay a dividend?
VBI Vaccines Inc. (VBIV) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VBIV go public?
VBI Vaccines Inc. (VBIV) completed its initial public offering in 2010.